SOLICITATION NOTICE
Q -- Services regarding classification of morphology, immunophenotype, molecular, and virological characteristics of Burkitt lymphoma
- Notice Date
- 8/18/2010
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100180-AV
- Archive Date
- 9/17/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Infections and Immunoepidemiology Branch (IIB) plans to procure on a sole source basis with the University of Southern California; 1441 Eastlake Ave., Room 4423; Los Angeles, CA 90033 for services regarding classification of morphology, immunophenotype, molecular, and virological characteristics of Burkitt lymphoma. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541380 and the business size standard is $12M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for eleven (11) months from date of award. The National Cancer Institute (NCI) is evaluating the morphology, molecular, and virological characteristics of tumors diagnosed and coded as Burkitt lymphoma in the U.S. Burkitt lymphoma (BL) occurs as three variants; endemic, sporadic, and AIDS-related, which share tumor cell morphology and an obligate translocation between cellular-MYC and immunoglobulin genes. The timing and causes of translocation/transformation to BL are unknown. Epstein-Barr virus (EBV), which is implicated in 95% of endemic BL cases, is less important in sporadic BL, where it is detected in at most 20% of cases. The patterns of EBV-positivity in sporadic BL by age or race, which are correlated with risk of EBV infection, are unknown. Descriptive study of age-related risk for BL using SEER data revealed incidence peaks near ages 10, 40, and 75 years, among males and two peaks at 10 and 75 years among females. The risk for BL was 4-fold higher in males than females less than 60 years but only 2-fold higher in persons older than 60 years. The peaks could mean: 3 different causes; one cause, but 3 different intrinsic "age-effects"; one cause but 3 different co-factors that are age and may be sex-related. NCI hypothesizes that the age peaks are characterized by molecular and virological characteristics. The required samples (250 in total) will be sent from the SEER Residual Tissue Repository (RTR) to the proposed Contractor. This data is critical for the study and RTR will only release the slides to Southern California University. The samples will be residual pathology tissue of registered cases, clinical and demographical data, as well as formalin-fixed paraffin-embedded (FFPE) tissue blocks for BL cases with residual tissue. Population-based samples are needed to correlate morphological, molecular, and virological patterns in the tumor to age, sex, and racial-patterns of Burkitt lymphoma. The Contractor shall review the samples from the repository for diagnosis of BL to classify the various characteristics of the disease across all ages. There are no other sources known to the NCI that can perform this service to maintain consistent data and results because the SEER Residual Tissue Repository (RTR) will only release their data to Southern California University. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on September 2, 2010. For further information, please contact Ashley Virts, Contract Specialist via electronic mail at virtsa@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100180-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100180-AV/listing.html)
- Record
- SN02245392-W 20100820/100818235528-43f866de4cd0d6815f3ea8862812c572 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |